HLA Haplotypes as Biomarkers for COVID-19 Severity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the severity of SARS-CoV-2 infection in individuals are inadequate, as they rely primarily on age and BMI, failing to account for other significant risk factors, which limits the accuracy of identifying those at high risk for severe symptoms and necessitates improved risk assessment strategies.
Innovation Solution
The use of specific HLA haplotypes, such as DQA1*01:02/DQB1*06:02, DRB1*15:01, DQA1*05:01/DQB1*02:01, and vitamin D status as biomarkers to assess the risk of developing severe symptoms, incorporating surrogate markers like latitude and ethnicity to estimate vitamin D levels, allowing for personalized risk evaluation and targeted interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If age and BMI are used as the only risk factors for predicting severe SARS-CoV-2 infection, then the assessment method is simple and easy to apply, but the prediction accuracy is insufficient and fails to identify all high-risk individuals
Solution Approach 1:
The risk assessment is segmented into multiple independent components: HLA haplotype testing, vitamin D status assessment, and traditional risk factor evaluation. Each component can be assessed separately and combined to provide comprehensive risk stratification, improving accuracy without requiring all assessments to be performed simultaneously
Solution Approach 2:
The assessment moves from two-dimensional (age and BMI) to multi-dimensional evaluation by incorporating genetic (HLA haplotypes) and nutritional (vitamin D status) dimensions. This adds new axes to the risk prediction model, enabling identification of high-risk individuals who would be missed by traditional factors alone
2Reliability
If HLA haplotype testing and vitamin D status assessment are added to risk evaluation, then the identification of high-risk individuals improves, but the complexity of the assessment process increases
Solution Approach 1:
HLA haplotype typing and vitamin D status assessment are performed in advance on asymptomatic individuals before SARS-CoV-2 infection occurs. This preliminary characterization enables proactive identification of high-risk individuals who can then be monitored and targeted for interventions before infection happens
Solution Approach 2:
The patent introduces intermediary risk categories (high risk, medium risk, low risk) that mediate between the complex multi-factor assessment and clinical decision-making. These categories simplify the output of the complex assessment process into actionable guidance for healthcare professionals
3Adaptability or versatility
If comprehensive risk factors including HLA haplotypes and vitamin D status are assessed, then the ability to prioritize vaccination and treatments improves, but the cost and resource requirements increase
Solution Approach 1:
The comprehensive assessment is applied locally to identify specific high-risk individuals rather than applying uniform measures to the entire population. By characterizing risk at the individual level using HLA haplotypes and vitamin D status, resources can be targeted precisely to those who need them most, improving intervention effectiveness while controlling overall resource consumption
Data Source
AI summary
The present invention relates to methods, devices and kits for identifying individuals who are at increased risk of developing severe symptoms associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The present invention also relates to methods, devices and kits for identifying individuals who have a reduced risk of developing severe symptoms associated with SARS-CoV-2 infection. In particular, it relates to the use of HLA haplotypes as biomarkers to predict disease severity in individuals infected with SARS-CoV-2.